Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277695 | 0.85 | BCL3 (0.46) | BCL3NPC1RAB9AMCHR1HTR4 | |
| SCHEMBL7982043 | 0.82 | NPC1 (0.64) | NPC1RAB9ACHRM4RPS6KB1 | |
| Acetic Acid SCHEMBL6454337 | 0.80 | NPC1 (0.59) | NPC1RAB9ACHRM4RPS6KB1HTR4 | |
| SCHEMBL27304799 | 0.73 | RAB9A (0.51) | BCL3NPC1RAB9ARPS6KB1KMT2A | |
| SCHEMBL6397852 | 0.72 | CCR3 (0.61) | BCL3KCNH2 | |
| SCHEMBL16459248 | 0.72 | SMYD3 (0.49) | MCHR1HTR4CACNA1HCYP2D6KCNH2 | |
| SCHEMBL16163289 | 0.72 | CHRM1 (0.53) | NPC1RAB9ACHRM4RPS6KB1 | |
| SCHEMBL12121083 | 0.72 | CNR2 (0.55) | NPC1RAB9ACHRM4 | |
| SCHEMBL14763383 | 0.71 | CHRM4 (0.62) | MCHR1CHRM4 | |
| SCHEMBL16825763 | 0.71 | RPS6KB1 (0.50) | NPC1RAB9ARPS6KB1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | BCL3 1821/4885NPC1 1266/4885RAB9A 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.